Drug Trial Radar · NCT06915025
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Jul 9, 2025
Primary completion
Oct 31, 2032
Study completion Oct 31, 2032
Sponsor
- Lead sponsor
- ImunonIndustry
- Sponsor type
- Industry
- First posted
- Apr 7, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, adaptive, open label, multicenter trial to evaluate the safety and efficacy of intraperitoneal (IP) IMNN-001 plus chemotherapy compared to chemotherapy alone.
Conditions
- Epithelial Ovarian Cancer
- Ovarian Cancer
- Fallopian Tube Cancer
- Primary Peritoneal Carcinoma
Interventions
IMNN-001 (IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer)Drug
100 mg/m2 IP given weekly during frontline treatment
PaclitaxelDrug
175 mg/m2 IV given every 21 days for 6 cycles during frontline treatment
CarboplatinDrug
AUC 6 IV given every 21 days for 6 cycles during frontline treatment
OlaparibDrug
Olaparib (300 mg orally every 12 hours for 2 years) for patients with somatic or germline BRCAmut.
NiraparibDrug
Niraparib (200-300 mg orally daily for 3 years; dosing based on participant's weight and platelet counts) for either HRD/BRCAmut \& HRD/BRCAwt.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 48 months
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Advent Health
Orlando, Florida · Recruiting
Louisiana State University HSC - NO Cancer Center
New Orleans, Louisiana · Recruiting
Karmanos Cancer Institute
Detroit, Michigan · Recruiting
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
University of Rochester Medical Center
Rochester, New York · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
Sanford Health
Sioux Falls, South Dakota · Recruiting
Erlanger Health
Chattanooga, Tennessee · Recruiting
Providence Sacred Heart Medical Center & Children's Hospital
Spokane, Washington · Recruiting
Froedtert and The Medical College of Wisconsin
Milwaukee, Wisconsin · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.